Overestimation of anticoagulant benefit in patients with atrial fibrillation and low life expectancy: evidence from 12 randomized trials.
Sachin J ShahCarl van WalravenSun Young JeonW John BoscardinFd Richard HobbsStuart ConnollyMichael EzekowitzKenneth E CovinskyMargaret C FangDaniel E SingerPublished in: medRxiv : the preprint server for health sciences (2023)
-VASc, which does not account for the competing risk of death nor decelerating treatment benefit over time. Overestimation was most pronounced in patients with the lowest life expectancy and when benefit was estimated over a multi-year horizon.